Fatemeh
Fatemeh Abbasinejad, Davis, CA US
Patent application number | Description | Published |
---|---|---|
20130076619 | Methods and Apparatus for Freeform Deformation of 3-D Models - Methods and apparatus for interactive curve-based freeform deformation of three-dimensional (3-D) models may provide a user interface that allows a user to interactively deform 3-D models based on simple and intuitive manipulations of a curve drawn on the model (i.e., freeform deformation). The user may apply freeform deformations using touch and/or multitouch gestures to specify and manipulate a deformation curve. The deformations may be applied by deforming the space around a curve/sweep path and deforming the 3-D model accordingly. The freeform deformation methods are not dependent on manipulation of a fixed set of parameters to perform deformations, and may provide for both local and global deformation. One or more weights and user interface elements for controlling those weights may be provided that allow the user to control the extent (region of influence) of the freeform deformations along the curve and/or perpendicular to the curve. | 03-28-2013 |
20130127848 | System and Method for Generating 3D Surface Patches from Unconstrained 3D Curves - Various embodiments of a system and methods for generating 3D surface patches from unconstrained 3D curves are described. The system may receive a set of unconstrained 3D wireframe curves that represent a 3D wireframe model. The 3D wireframe curves may be unorganized, may have inconsistent orientations, and may have an arbitrary number and type of curve intersections. The system may automatically generate the 3D surface patches, dependent on the 3D wireframe curves. The 3D surface patches may form a 3D surface that connects the 3D wireframe curves. The 3D surface patches may be generated from faces of the 3D wireframe model. The faces may be elementary cycles extracted from the 3D wireframe model. The system may receive user input which indicates changes to the 3D surface patches. A user may change, create, and/or delete 3D surface patches to achieve a desired 3D surface that represents the 3D wireframe model. | 05-23-2013 |
Fatemeh Ahmadnian, Berlin DE
Patent application number | Description | Published |
---|---|---|
20110224396 | PROCESS FOR PREPARING POLYETHER POLYOLS - The present invention relates to a process for the catalytic preparation of polyetherols, wherein the power input by means of at least one stirrer and/or by means of at least one pump, based on the reactor volume, is in the range from 0.001 to 8.2 kW/m | 09-15-2011 |
20110251345 | DEODORIZATION OF POLYMER COMPOSITIONS - The present invention relates to a method for reducing residual volatiles from polymer compositions. | 10-13-2011 |
Fatemeh Ahmadnian, Ludwigshafen DE
Patent application number | Description | Published |
---|---|---|
20130023700 | PROCESS FOR A CONTINUOUS PRODUCTION OF POLYETHEROLS - A process for a continuous production of a polyetherol first involves reacting an alcohol with a starter or an alkoxylated precursor, to give a mixture comprising an alcoholate and water. Water is then removed from the mixture. The process further involves feeding the alcoholate into a bubble column and feeding an alkylene oxide into the bottom of a compartment of the bubble column, such that the alkylene oxide rises in the alcoholate. The alkylene oxide then reacts with the alcoholate or a secondary product from the reaction between the alcoholate and alkylene oxide, to give the polyetherol. | 01-24-2013 |
20150225336 | PROCESS FOR THE PURIFICATION OF A POLYCARBODIIMIDE - A process for purifying a polycarbodiimide comprising (a) providing a mixture comprising a polycarbodiimide and a carbodiimidization catalyst; (b) separating carbodiimidization catalyst from the polycarbodiimide by subjecting the mixture according to (a) to a first distillation, (c) adding an entrainer to the first bottom product obtained from (b) to obtain a mixture; (d) further separating carbodiimidization catalyst from the polycarbodiimide by subjecting the mixture obtained from (c) to a second distillation. | 08-13-2015 |
Fatemeh Akhlaghi, Wakefield, RI US
Patent application number | Description | Published |
---|---|---|
20080255765 | MONITORING CYCLOSPORINE IN SALIVA - Saliva offers an alternative specimen for the therapeutic monitoring of cyclosporine (CsA) in children and patients with difficult venous access. For a highly protein-bound drug such as CsA, saliva provides a practical approach for measuring the unbound concentration. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is ideally suited for the measurement of drugs in saliva. A solid-phase extraction technique, analytic liquid chromatography over an Aqua Perfect column, maintained at 65° C., and electrospray tandem mass spectrometry were used to quantify CsA in saliva. The method used cyclosporine C (CsC) as the internal standard. Mobile phase comprised of a 97:3 voL mixture of methanol and 30 mmol/L ammonium acetate at a flow rate of 0.5 mL/min. Chromatograms using mass transitions of m/z 1219.9→m/z 1202.9 for CsA and m/z 1235.9→m/z 1218.9 for CsC were obtained. The calibration curve was linear from 1 to 300 μg/L with correlation coefficient values ranging from 0.9732 to 0.9968). The lower limit of quantification was 1 μg/L and limit of detection was 0.6 μg/L with an average extraction recovery of 84.7±2.6% for CsA and 93.7±4.4% for CsC from the saliva matrix. The accuracy of the method ranged from 92% to 104.7%, and the intra- and interim coefficients of variation were 6.9-12.2% and 8.3-12.1%, respectively. The correlation coefficient value between the CsA concentration measurements in 15 paired blood-saliva samples from kidney transplant recipients was 0.695 (P=0.006). The noninvasive and simple method of saliva collection coupled with the LC-MS/MS quantification technique for CsA analysis would generate novel data that could benefit patients undergoing CsA therapy. | 10-16-2008 |
20080318322 | ANALYSIS OF MYCOPHENOLIC ACID IN SALIVA USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY - A method for mass spectrometric analysis of a saliva sample possibly containing mycophenolic acid or its metabolites mycophenolic acid phenyl glucuronide (MPAG) or mycophenolic acid acyl-glucuronide (Acyl-MPAG), including the steps: (a) providing a saliva sample containing one or more drug or metabolites; (b) deproteinating the sample; (c) separating the one or more drug or metabolites from the saliva sample; and (d) analyzing the one or more drug or metabolites using a mass spectrometer. The sample containing one or more MPA or metabolites is obtained from in an oral fluid based biological samples i.e. whole saliva or saliva obtained by chemical or mechanical stimulation or from specific salivary glands. The size of the sample contains one or more MPA or metabolites is at least about 100 microL. A kit for use in mass spectrometric analysis of a sample may contain one or more MPA or metabolites from saliva samples, comprising: (a) reagents for deproteinating of the saliva sample, including internal standards; (b) reagents for separating the one or more MPA or metabolites from the saliva sample; (c) reagents for analyzing the one or MPA or metabolites using a mass spectrometer; (d) a solution of one or more MPA or metabolites in saliva samples; and (e) instructions for analyzing the one or more MPA or saliva using a mass spectrometer. The kit includes (a) mobile phase solutions; (b) a chromatography column; and (c) a quality control specimen. | 12-25-2008 |
20110281369 | ANALYSIS OF MYCOPHENOLIC ACID IN SALIVA USING LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY - A method for mass spectrometric analysis of a saliva sample possibly containing mycophenolic acid or its metabolites mycophenolic acid phenyl glucuronide (MPAG) or mycophenolic acid acyl-glucuronide (Acyl-MPAG), including the steps: (a) providing a saliva sample containing one or more drug or metabolites; (b) deproteinating the sample; (c) separating the one or more drug or metabolites from the saliva sample; and (d) analyzing the one or more drug or metabolites using a mass spectrometer. The sample containing one or more MPA or metabolites is obtained from in an oral fluid based biological samples i.e. whole saliva or saliva obtained by chemical or mechanical stimulation or from specific salivary glands. The size of the sample contains one or more MPA or metabolites is at least about 100 microL. A kit for use in mass spectrometric analysis of a sample may contain one or more MPA or metabolites from saliva samples, comprising: (a) reagents for deproteinating of the saliva sample, including internal standards; (b) reagents for separating the one or more MPA or metabolites from the saliva sample; (c) reagents for analyzing the one or MPA or metabolites using a mass spectrometer; (d) a solution of one or more MPA or metabolites in saliva samples; and (e) instructions for analyzing the one or more MPA or saliva using a mass spectrometer. The kit includes (a) mobile phase solutions; (b) a chromatography column; and (c) a quality control specimen. | 11-17-2011 |
Fatemeh Atyabi, Tehran IR
Patent application number | Description | Published |
---|---|---|
20100324315 | POLY(CITRIC ACID) FUNCTIONALIZED CARBON NANOTUBE DRUG DELIVERY SYSTEM - A method for synthesizing carbon nanotube drug carriers and the carbon nanotube drug carriers are disclosed. Initially, carbon nanotubes, nitric acid, and sulfuric acid are mixed to oxidize carbon nanotubes in a first mixture. The oxidized carbon nanotubes are then extracted from the first mixture. The oxidized carbon nanotubes and monohydrated citric acid are mixed to synthesize carbon nanotubes grafted with poly(citric acid) in a second mixture. The carbon nanotubes grafted with poly(citric acid) are then extracted from the second mixture. The carbon nanotubes grafted with poly(citric acid) and 4-(dimethylamino)pyridine are dissolved in anhydrous dimethylformamide in a third mixture. Next, a mixture that comprises a drug is added to the third mixture to synthesize the carbon nanotubes grafted with poly(citric acid) and the drug in a fourth mixture. Then, the carbon nanotubes grafted with poly(citric acid) and the drug are extracted from the fourth mixture. | 12-23-2010 |
Fatemeh Azmandian, Taunton, MA US
Patent application number | Description | Published |
---|---|---|
20110004935 | VMM-BASED INTRUSION DETECTION SYSTEM - An intrusion detection system collects architectural level events from a Virtual Machine Monitor where the collected events represent operation of a corresponding Virtual Machine. The events are consolidated into features that are compared with features from a known normal operating system. If an amount of any differences between the collected features and the normal features exceeds a threshold value, a compromised Virtual Machine may be indicated. The comparison thresholds are determined by training on normal and abnormal systems and analyzing the collected events with machine learning algorithms to arrive at a model of normal operation. | 01-06-2011 |
Fatemeh Davami, Tehran IR
Patent application number | Description | Published |
---|---|---|
20120058537 | CHIMERIC TRUNCATED AND MUTANT VARIANT OF TISSUE PLASMINOGEN ACTIVATOR (T-PA) RESISTANT TO PLASMINOGEN ACTIVATOR INHIBITOR-1 - The various embodiments herein provide a chimeric truncated and mutant variant of a tissue plasminogen activator (t-pa) and a method for preparing the same. According to an embodiment herein, the mutant variant comprises a signal sequence domain, followed by a chimeric tetrapeptide, followed by a tripeptide, followed by a kringle 2 domain, followed by a serine protease domain and a substituted amino acids at position 128-131. The substituted amino acids are AAAA (SEQ ID NO: 3) amino acids. The chimeric tetrapeptide is Gly-His-Arg-Pro (SEQ ID NO: 1). The chimeric tetrapeptide is at a position of 36 to 39 amino acid of the mutant variant. The tripeptide is Ser-Tyr-Glu. According to an embodiment herein, a chimeric truncated and mutant variant of a tissue plasminogen activator comprises a native t-pa deleted with Finger domain, a Growth Factor domain and a Kringle 1 domain, a chimeric tetrapeptide and a substituted amino acids at a position of 128-131. | 03-08-2012 |
20150132826 | CHIMERIC TRUNCATED TISSUE PLASMINOGEN ACTIVATOR (t-PA) RESIATANT TO PLASMINOGEN ACTIVATOR INHIBITOR-1 AND IMPROVED BIOCHEMICAL PROPERTIES - The present invention discloses a thrombolytic therapy for acute myocardial infarction by t-PA. A chimeric truncated form of t-PA is designed and expressed in | 05-14-2015 |
20150259666 | CHIMERIC TISSUE PLASMINOGEN ACTIVATOR (T-PA) RESIATANT TO PLASMINOGEN ACTIVATOR INHIBITOR-1 AND IMPROVED BIOCHEMICAL PROPERTIES - The present invention discloses the thrombolytic therapy by t-PA or CT-b for the treatment of the acute myocardial infarction. A chimeric truncated form of t-PA or CT-b is designed and expressed in | 09-17-2015 |
Fatemeh Davar, Kashan IR
Patent application number | Description | Published |
---|---|---|
20120034465 | METHOD FOR PREPARING SILICA-DYSPROSIUM OXIDE CORE-SHELL NANOPARTICLES - Silica-dysprosium oxide core-shell nanoparticles and a method for preparing the silica-dysprosium oxide core-shell nanoparticles are disclosed. Initially, ethyl silicate, n-butanol, ethylenediamine, and distilled water are mixed in the presence of ultrasonic radiation to prepare silica nanoparticles. Then, the silica nanoparticles are isolated. Next, the isolated silica nanoparticles, an acid, n-butanol, and dysprosium oxide are mixed in the presence of ultrasonic radiation to prepare silica-dysprosium oxide core-shell nanoparticles. Finally, the silica-dysprosium oxide core-shell nanoparticles are isolated. | 02-09-2012 |
Fatemeh Hajibagher, Debrecen HU
Patent application number | Description | Published |
---|---|---|
20110180672 | Airplane with aerodynamic stall-prevention layout and pertinent longitudinal stability arrangement - General purpose airplane with a swept back wing provided with a sharp leading edge as to cause flow separation and stall of the wing in cases where the limits of the regular flight envelope are exceeded in terms of angle of attack, and as a result to cause the front part of the airplane to move downward, said airplane also having positive lift-producing horizontal stabilizer provided with rounded leading edge, which does not stall at this point, therefore holds the tail in level during the process, all together acting to restore the original flight attitude. The horizontal stabilizer is essentially a straight (or similar) wing with a steeper lift-coefficient curve as that of the swept-back wing, therefore, in case of an un-commanded pitch-up of the airplane the greater increase of lift on the horizontal stabilizer together with its greater moment arm provides the stabilizing force to counter such pitching. | 07-28-2011 |
Fatemeh Hassanipour, Plano, TX US
Patent application number | Description | Published |
---|---|---|
20140263278 | SOLAR SELECTIVE MULTILAYER COATING - The present invention provides a method for making a highly efficient and inexpensive solar selective coating. Coating consists of various carbon nanotube sheets composite layers, each performing a specific function by incorporating functional materials and components with proper structure. Joule heating of the described solar selective coating allows for efficient functionality even when solar energy is not available. | 09-18-2014 |
20150040888 | INTEGRATION OF PHASE CHANGE MATERIALS INSIDE EVACUATED TUBE SOLAR COLLECTOR FOR STORAGE AND TRANSFER OF THERMAL ENERGY - An objective of the invention is to design and develop an effective method to collect and store heat in a solar collector for delayed release. An embodiment of the invention is directed to an evacuated tube collector, where PCM is placed directly inside the void space of the collector tube, next to the heat pipe. The heat pipe is located with phase change material (PCM) in such a way that its thermal connection with the heat pipe can be switched “ON” to start heat transfer from PCM or “OFF” to keep latent heat stored in PCM for delayed usage. In additional, flow of heat exchange fluid through the manifold can enable release of stored heat of PCM to storage tank. Delayed release of accumulated heat in PCM enables added functionality of on-demand operation of SWH. | 02-12-2015 |
Fatemeh Maleky, Kitchener CA
Patent application number | Description | Published |
---|---|---|
20100143644 | APPARATUS AND METHOD FOR SOLIDIFYING A MATERIAL UNDER CONTINUOUS LAMINAR SHEAR TO FORM AN ORIENTED FILM - A method of solidifying a fluid comprising a material into an oriented film. The method includes pumping the fluid into a channel at an input end thereof at a predetermined pressure sufficient to push the material to an output end of the channel. The channel is at least partially defined by a substantially smooth outer surface of an inner tube and a substantially smooth inner surface of an outer tube. The method also includes subjecting the material to laminar shear at a predetermined rate by rotating one of the inner tube and the outer tube relative to the other. The predetermined rate is selected to promote solidification of the fluid into the oriented film. Also, the method includes cooling the material at a predetermined rate as the material moves through the channel from the input end to the output end to promote solidification of the fluid into the oriented film. | 06-10-2010 |
Fatemeh Mojtabai, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20080219592 | Self-similar ordered microstructural arrays of amphiphilic molecules - The invention pertains, at least in part, to a method for determining the structure of an amphiphilic molecule using Self-Similar Microstructure Arrays. | 09-11-2008 |
Fatemeh Mojtabai, Weston, MA US
Patent application number | Description | Published |
---|---|---|
20140180603 | SELF-SIMILAR ORDERED MICROSTRUCTURAL ARRAYS OF AMPHIPHILIC MOLECULES - The invention pertains, at least in part, to a method for determining the structure of an amphiphilic molecule using Self-Similar Microstructure Arrays. | 06-26-2014 |
Fatemeh Mojtabai, Demarest, NJ US
Patent application number | Description | Published |
---|---|---|
20110218120 | ORDERED TWO- AND THREE-DIMENSIONAL STRUCTURES OF AMPHIPHILIC MOLECULES - The invention pertains, at least in part, to a method for forming an ordered structure of amphiphilic molecules, such as proteins. The method includes contacting a population of amphiphilic molecules with a interface; compressing said population laterally to an appropriate pressure, such that an ordered structure at the interface is formed. The invention also pertains to the two- and three-dimensional ordered structures that are formed using the planar membrane compression method of the invention. | 09-08-2011 |
Fatemeh Rahbarizadeh, Tehran IR
Patent application number | Description | Published |
---|---|---|
20130178603 | MULTI-MODE CANCER TARGETED NANOPARTICULATE SYSTEM AND A METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide a method of synthesizing a multi-mode cancer targeted nanoparticles. The method comprises the steps of preparing a plurality of nanoparticles and covalently conjugating monoclonal antibodies on surface of the prepared plurality of nanoparticles. The plurality of nanoparticles consists of a protein and a drug. The protein is Human Serum Albumin protein (HSA) and the drug is methotrexate. The monoclonal antibodies are anti-MUC1 nanobodies. According to an embodiment herein, a multi-mode cancer targeted nanoparticles comprising a plurality of cross linked nanoparticles of protein and drug molecules and covalently linked molecules of monoclonal antibodies. The molecules of monoclonal antibodies are linked on a surface of the plurality of cross linked nanoparticles. | 07-11-2013 |
Fatemeh Razavi-Shirazi, Hayward, CA US
Patent application number | Description | Published |
---|---|---|
20130337517 | ENHANCED EFFICIENCY ETHANOL AND SUGAR CONVERSION PROCESSES - Overlay processes are disclosed for making ethanol that not only increase ethanol conversion but do so in a cost effective manner with a reduction in energy requirements per unit of ethanol production. The processes can provide, if desired, higher organic compound as a co-product with ethanol. | 12-19-2013 |
20130337518 | NOVEL BIOCATALYST COMPOSITIONS AND PROCESSES FOR USE - The microorganism-containing biocatalysts disclosed have a large population of the microorganisms irreversibly retained in the interior of the biocatalysts. The biocatalysts possess a surprisingly stable population of microorganisms and have an essential absence of debris generation from metabolic activity of the microorganisms. The biocatalysts are composed of highly hydrophilic polymer and have an internal, open, porous structure that promotes community phenotypic changes. | 12-19-2013 |
20140106420 | BIOCONVERSION PROCESSES USING WATER-INSOLUBLE LIQUIDS - Processes are disclosed for bioconversion processes in which a ME biocatalyst is surrounded by water-insoluble liquid during the bioconversion to facilitate one or more of mass transfer of substrate to and bioproduct from the biocatalyst and the separation and recovery of bioproduct from the water-insoluble liquid. The ME biocatalyst irreversibly retains microorganisms for the bioconversion and has, in its interior, an aqueous environment. | 04-17-2014 |
20140106425 | BIOPROCESSES FOR MAKING BUTANOL - Butanol is produced by the bioconversion of substrate using a biocatalyst comprising an open, porous hydrophilic polymeric structure having microorganisms for the bioconversion irreversibly retained therein wherein the microorganisms have undergone phenotypic alterations which includes enhanced tolerance to butanol. | 04-17-2014 |
20140367333 | NOVEL BIOCATALYST COMPOSITIONS AND PROCESSES FOR USE - The microorganism-containing biocatalysts disclosed have a large population of the microorganisms irreversibly retained in the interior of the biocatalysts. The biocatalysts possess a surprisingly stable population of microorganisms and have an essential absence of debris generation from metabolic activity of the microorganisms. The biocatalysts are composed of highly hydrophilic polymer and have an internal, open, porous structure that promotes community phenotypic changes. | 12-18-2014 |
20150125901 | BIOCONVERSION PROCESSES AND APPARATUS - Bioconversion processes are disclosed in which two or more biocatalysts including microorganisms or isolated enzymes that are substantially irreversibly retained in the interior of an open, porous, highly hydrophilic polymer are used in a common aqueous medium. In one exemplary embodiment, one biocatalyst produces a chemical product that is a substrate to at least one other biocatalyst. In another exemplary embodiment, the feed includes two or more substrates and one biocatalyst bioconverts at least one substrate and another biocatalyst bioconverts at least one other substrate. This aspect is particularly useful for treating water including disparate contaminants by metabolic degradation in a bioreaction zone including multiple types of biocatalysts. | 05-07-2015 |
20150151997 | PROCESSES FOR THE BIODEGRADATION OF NDMA - NDMA can be degraded by | 06-04-2015 |
20150191715 | NOVEL BIOCATALYST COMPOSITIONS AND PROCESSES FOR USE - The microorganism-containing biocatalysts disclosed have a large population of the microorganisms irreversibly retained in the interior of the biocatalysts. The biocatalysts possess a surprisingly stable population of microorganisms and have an essential absence of debris generation from metabolic activity of the microorganisms. The biocatalysts are composed of highly hydrophilic polymer and have an internal, open, porous structure that promotes community phenotypic changes. | 07-09-2015 |
Fatemeh Talaei, Groningen NL
Patent application number | Description | Published |
---|---|---|
20130203830 | Compounds for Prevention of Cell Injury - The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation. | 08-08-2013 |
Fatemeh Yarahmadi, Ahvaz IR
Patent application number | Description | Published |
---|---|---|
20150266789 | ORGANIC FERTILIZER COMPOSITION FROM CAMELLIA SINENSIS EXTRACT FOR PEST CONTROL AND A METHOD OF SYNTHESIZING THE SAME - The embodiments herein provide an organic fertilizer based on aquatic extraction of | 09-24-2015 |